


INTERPRETATION OF THE RESULTS

EACH TEST WINDOW (FLU A/B, SARS-CoV-2 AND RSV) MUST BE READ INDEPENDENTLY FROM EACH OTHER.

Perform the test within 15 minutes

after the foil pouch is opened.

15



DO NOT TOUCH soft head of swab

ORTANT use it immediately

DO NOT OPEN the swab until you are going to

₩

Biohazard

00000

Tube Stand

POSITIVE RESULTS


Only 20 tests/kit package contains

the tube stand. The other test kits

Specimen Bag have a holder for the tube

THE SHADE OF LINES MAY VARY, BUT EVEN IF A **FAINT/WEAK LINE APPEARS** IT SHOULD BE CONSIDERED POSITIVE.

If you have a POSITIVE result, follow the guidance from your local State or Territory Health Department for guidance on confirmation testing if necessary, and if unwell seek medical assistance for SARS-CoV-2 and individuals with a positive result or who are unwell must consult a medical practitioner for follow-up clinical care for Influenza and RSV



NEGATIVE RESULTS

And squeeze the tip of the swab 5 times

much liquid in the bottle as possible.

Squeeze it

along the inner wall of the tube to keep as


ONLY RED LINES APPEAR IN THE CONTROL REGIONS (C), AND NO LINE IN THE REGION (A), (B), AND (T).

The negative result indicates that there are no Flu A/B, RSV and SARS-CoV-2 particles in the sample or the number of viral particles is below the detectable range. Even if you get a negative result, you still need to follow all public health advice on limiting the spread Covid-19, Flu A/B and RSV. If symptoms persist, repeat testing and consult a medical practitioner for follow-up clinical care.

INVALID RESULTS

the specimen tube into the each sample well.

If adding less than 3 drops, that will yield wrong result.



number or email for assistance.

Watch "how to use" video:

touchaustralia.com.au/pages/ifu-covid-flu-rs

NEED HELP with the TEST?

Before You Start

Do not open the foil pouch and swab packaging until you have read the instructions, and are ready to take the test. Use immediately upon opening.

Will this test hurt?

 No. the nasal swab is not sharp and it should not hurt. Sometimes the swab can feel slightly uncomfortable. If you feel pain, please stop the test and seek advice from a doctor

When should I perform the test after opening the foil pouch?

• You should perform the test within 15 minutes after opening the foil pouch.

Don't know how long I should keep the swab out without using?

• Do not open the swab packaging until you are going to use it immediately.

What do you need to consider when storing the test kit?

• You can store the test kit at 2°C - 30°C temperature. Do not freeze and do not store the test kit in direct sunlight. All components must be bought to room temperature before testing. Do not use after expiry date.

Sample Collection

Do I need to insert the swab into my both nostrils to take sample?

• Yes, you must take the samples from your both nostrils.

Don't know how deep I should insert the swab into my nostrils?

• Gently insert the swab about 2cm (soft head of the swab) into your nostrils. Do not insert the swab deeper if you feel strong resistance or pain.

Test Operation

How many drops should I add in both sample wells?

• You should add 3 drops using the buffer tube into all three samples wells noted as "S" on the cassette

Don't know how long I should wait to read my results?

• Make sure you wait for 15 minutes, and then read your results at 15-20 minutes

Read Results

How do I know if the test was run properly?

. A coloured line will appear in the control region (C) of the test cassette if the test has been properly performed. If this line is not visible, then the test has been incorrectly performed and you must run a new test or call

There is a faint/weak line appearing at A, B or T, should this be still considered as positive?

• Yes, even if there is a faint line at the region A, B or T or all, results must be considered as positive.

The red line appeared in the control (C) region only on some of the strip/s and did not appear on one or two strips. Does that mean the test is invalid for all 3 viruses?

• No, it means test must be considered invalid only for those virus where red line is absent on control (C) region. Results are valid for any test where control region (C) is present.



Visit www.touchaustralia.com.au/pages/ifu-covid-flu-rsv to watch "how to use" video. If you have any specific questions, feedback or suggestion please contact us on the provided contact number or email address.



touch

TouchBio RSV. FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) REF: VMD71 (EN)

An Antigen Rapid Test for the detection of SARS-Cov-2. Flu A/B and RSV in nasal swab. For Self-Testing use.

In-vitro diagnostic test for self-testing

Instructions for use

INTENDED USE

TouchBio RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) is an in vitro immunochromatographic assay for the qualitative detection of antigens in nasal swab specimens collected from patients against the respiratory infection for SARS-CoV-2 (within the first 7 days of the onset of symptoms) and influenza A/B or Respiratory syncytial virus (RSV) (within the first 4 days of the onset of symptoms). This test is intended for use as an aid in the differential diagnosis of SARS-CoV-2 and influenza A/B or Respiratory syncytial virus (RSV) viral infections in humans in conjunction with clinical and epidemiological risk factors. The test does not require any special training for sample collection, processing, or test operation. TouchBio RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) is intended to be used by laypersons as a self-test. The test can be performed by individuals older than ≥ 18 years old and users between 4-18 years old required guidance by adults. This kit is not suitable for children under 4 years old.

PRINCIPLE OF THE TEST

TouchBio RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) is an immunochromatographic membrane assay and contains 3 independent tests. the SARS-CoV-2 antigen test, FLU A/B antigen test and RSV antigen test. In the test procedure, a specimen is collected by nasal swab and placed onto sample well of test cassette as 3 drops then allow the solution in the sample well to migrate through the pads containing highly sensitive detector antibodies conjugated to gold dye for detection of nucleocapsid antigens.

MATERIALS AND COMPONENTS

Materials required and provided with the test kits

Test Device	1 Test cassette (1 Test/pouch x 1 pouch)	2 Test cassettes (1 Test/pouch x 2 pouches)	5 Test cassettes (1 Test/pouch x 5 pouches)	20 Test cassettes (1 Test/pouch x 20 pouches)
Extraction Buffer Tube	1 single-use bottle, each with 500 µL extraction buffer	2 single-use bottles, each with 500 µL extraction buffers	5 single-use bottles, each with 500 µL extraction buffers	20 single -use bottles, each with 500 μL extraction buffers
Sterilised Swab	1 sterile, single use specimen sampling swab	2 sterile, single use specimen sampling swabs	5 sterile, single use specimen sampling swabs	20 sterile, single use specimen sampling swabs
Biohazard Specimen Bag	1 biohazard specimen bag	2 biohazard specimen bags	5 biohazard specimen bags	20 biohazard specimen bags
Instructions For Use	1 instructions for use	1 instructions for use	1 instructions for use	4 instructions for use
Tube Stand	-	-	-	1 Tube Stand

Materials required but not provided with the test kit

STORAGE AND STABILITY

- Store the test kit at 2°C 30°C. DO NOT FREEZE and DO NOT STORE the test kit in direct sunlight. All components must be brought to room temperature before testing.
- 2. The test cassette must be used within 15 minutes after removal from th foil pouch
- 3. DO NOT USE after the expiry date. The expiry date is stated on the label/packaging.

LIMITATIONS

1. Each test can only be used once

with other viruses

- 2. Test results must be read at 15 minutes and no later than
- 3. A negative result does not rule out infection with another type of respiratory virus (other than SARS-Cov-2, Influenza A/B and RSV). 4. A negative result does not mean a person is not infectious or does not have COVID-19, Influenza A/B or RSV. If symptoms persist the person should seek medical attention and further testing if required. 5. Positive test results do not rule out bacterial infection or coinfection

- 6. A false negative test may result if the level of antigen in the sample is below the detection limit of the test or if the sample was collected incorrectly.
- 7 If the result is positive for SARS-CoV-2 please contact the relevant state or territory health authority for guidance on confirmation testing. 8.If positive for Influenza A/B or RSV are feeling unwell, consult a medical practitioner for follow-up clinical care...
- 9 The test is less reliable in the later phase of infection and in asymptomatic individuals.
- 10. Children aged 4-18 years old should have the samples collected and tested by an adult. Do not use on Children under 4 years of age.
- 11. False negative results are more likely to occur if the test is performed after 7 days of symptom onset for SARS-CoV-2 and after 4 days of symptom onset for Influenza A/B and RSV.
- 12. Even if the result is negative, you still need to observe all protective and hygienic measures
- 13. Repeat Testing is recommended (between 24-48 hours after your first test if there is ongoing suspicion of infection, being high risk settling or where there is an occupational risk or other requirement
- 14. Influenza and RSV self-testing is for use as an aid for diagnosis only and individuals with a positive result or who are unwell are advised to consult a medical practitioner for follow-up clinical care.

QUALITY CONTROL

A colored line in the control area (C) is considered an internal process control. It confirms complete penetration of the membrane with the sample, reactivity of the reagents, and correct test performance.

PERFORMANCE CHARACTERISTICS

Clinical Study Performance

The clinical performance of the kit was determined by comparison with an RT-PCR assay. Individual kits used in the clinical performances included combination antigen rapid test for COVID-19+FLU A/B and antigen rapid test for RSV. Samples were taken within first 4 days of symptoms onset for Influenza A+B, RSV and samples taken within 7 days of symptoms onset for SARS-CoV-2. The performance of the kit was assessed with 261 positive SARS-CoV-2 case, 223 positive cases of RSV 160 positive Influenza A case, and 120 positive influenza B case by nasal swabs.

SARS-CoV-2

TouchBio	PCR-RT comparative test result				
RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test	Positive (+)	Negative(-)	Total		
Positive	258	4	262		
Negative	3	487	490		
Total	261	491	752		
Sensitivity: 258/261 x 10	00% = 98.85%		96.68% to 99.76%		
Specificity: 487/491 x 100% = 99.19%			97.93% to 99.78%		
Accuracy: (258+487)/752 x 100% = 99.07%			98.09% to 99.62%		

TouchBio RSV.		Infulenza A	za A		Infulenza B		
FLU A/B & Covid-19	RT-PCR Comparison Method		RT-PCR Comparison Method				
Rapid Antigen Combo Test	Positive	Negative	Total	Positive	Negative	Total	
Positive	157	2	159	118	2	120	
Negative	3	213	216	2	203	205	
Total	160	215	375	120	205	325	
Sensitivity:	98.12%	94.62% to 99.61%		98.33%	94.11%	to 99.80%	
Specificity:	99.07%	96.68% to 99.89%		99.02%	96.52%	to 99.88%	
Accuracy:	98.67%	96.92% to 99.57%		98 77%	96.88%	to 99.66%	

TouchBio	RT-PCR comparison method			
RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test	Positive	Negative		Total
Positive	220 1		1	221
Negative	3	230		233
Total	223 2		131	454
Sensitivity	98.65%		95% CI	96.12% to 99.72%
Specificity	99.57%		95% CI	97.61% to 99.99%
Accuracy	99.12%		95% CI	97.76% to 99.76%

Usability Study Performance

A total of 778 layusers took part in the TouchBio RSV, FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) study. Results are summarized below.

Results for SARS-CoV-2:

The sensitivity is 98.28% and the specificity is 99.49%. The accuracy of the test is calculated as 99.04%.

RSV, FLU A/B & Covid-19	RT-PCR comparison method				
Rapid Antigen Combo Test	Positive	Negative	Total		
Positive	114	1	115		
Negative	2	194	196		
Total	116	195	311		

The sensitivity is 98.39% and the specificity is 100.0%. The accuracy of the test kit is calculated as 99 21%

RSV, FLU A/B & Covid-19	R	T-PCR comparison meth	od
Rapid Antigen Combo Test	Positive	Negative	Total
Positive	183	0	183
Negative	3	195	198
Total	186	195	381

Results for Influenza B.

The sensitivity is 98.86% and the specificity is 100.0%. The accuracy of the test kit is calculated as 99.46%.

RSV, FLU A/B & Covid-19	RT-PCR comparison method			
Rapid Antigen Combo Test	Positive	Negative	Total	
Positive	174	0	174	
Negative	2	195	197	
Total	176	195	371	

The sensitivity is 97 14% and the specificity is 99 49%. The accuracy of the test kit

RSV, FLU A/B & Covid-19	RT-PCR comparison method			
Rapid Antigen Combo Test	Positive	Negative	Total	
Positive	102	1	103	
Negative	3	194	197	
Total	105	195	300	

Analytical Performance

1.Limit of Detection (LOD)

The minimum detection limit of the TouchBio RSV. FLU A/B & Covid-19 Rapid Antigen Combo Test (Nasal) is 100 TCID, JmL for SARS-CoV-2 infections. For Influenza A, the detection limit is minimum 1.0x10² TCID_{so} /mL (A/Victoria/3/75) and maximum 5.0x10⁴ TCID_{so}/mL (A/ HK/403946/09) and for Influenza B, the detection limit is minimum 6.0x102 TCID , /mL(B/1704) and maximum 4.0x104 TCID , /mL (B-Yamagata). For RSV, the detection limits is 240 TCID_/mL

2.Variants

2.1 SARS-CoV-2

B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).

2.2 Influenza A variants

H1N1, H3N2, H1N1pdm09, A/Taiwan/42/06, A/HongKong/8/68, A/Victoria/3/75, A/14160, A/HK/403946/09, A/44045, A/924, A/Beijing/302/54. A/swine/ Guangdong/2/01. S-OIV A/HK/415742/09. S-OIV A/California/4/09.

2.3.Influenza B variants

B-Victoria, B-Yamagata, B/1715, B/1704, B/179, B/668, B/Taiwan/2/62. B/ Malaysia/2506/2004

2.4.Respiratory syncytial virus (RSV) Variants RSV A and RSV B.

3. Analytical Specificity

3.1.Cross Reactivity

The cross-reactivity of the kit was evaluated. The results showed no cross-reactivity with the following samplesthe following samples. Adenovirus Type 3. Adenovirus Type 5. Adenovirus Type 7. Human Parainfluenza Type 1, Human Parainfluenza Type 2, Human Parainfluenza Type 3. Human Parainfluenza Type 4. Human coronavirus OC43. Human coronavirus NL63. Human coronavirus 229E. Respiratory syncytial virus Type A, Respiratory syncytial virus Type B, Rhinovirus Type 1, Rhinovirus Type 14, Rhinovirus B70, Enterovirus CA16, Enteroviru 70, Avian influenza virus H7N9, Avian influenza virus H5N1, Human para-flu virus Type 1, Human para-flu virus Type 2, Human para-flu virus Type 3, Human para-flu virus Type 4, Cytomegalovirus, Measles virus, Boca virus, Mumps virus, Epstein Barr Virus, Herpes simplex virus (HSV-1 Varicella-zoster virus, Human metapneumovirus, MERS coronavirus, SARS-coronavirus, Human coronavirus (HKU1), Bordetella pertussis. Bordetella parapertussia, Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae. Streptococcus salivarus. Escherichia coli. Candida albicans, Mycobacterium tuberculosis, Paramyxovirus parotitis, Pneumocystis iirovecii. Moraxella catarrhalis. Pseudomonas aeruginosa. Pneumocystis, Legionella pneumophila, Corynebacterium pneumophila, Lactobacillus pneumonhila Klehsiella pneumoniae Mycoplasma pneumoniae, Chlamydia pneumoniae, Neisseria pneumophila, Neisseria meningitides, Haemophilus influenza.

In silico analysis:

For Human Coronavirus HKU1, homology exists between the SARS-COV-2 nucleocapsid protein and Human Coronavirus HKU1. Blast results showed 36.6% homologous across 82% of the sequence.

This is relatively low but cross-reactivity cannot be fully ruled out. Blast results showed no homology or sequence similarity between RSV sequenece and HKU1. Mycobacterium tuberculosis & Pneumocystis jirovecii.

3.2.Interference Substances

The test results are not interfered by the substance in the following concentration. Whole Blood, Mucin, Benzocaine, Menthol, Zanamivir Mupirocin, Tobramycin, Fluticasone, Beclomethasone, Dexamethasone, Flunisolide, Triamcinolone, Mometasone, Sodium Chloride with preservative Phenylenhrine Afrin (Oxymetazoline) Ibunrofen Tetracycline Chloramphenicol, Erythromycin, Arbidol, Ribavirin, Histamine dihydrochloride, Throat spray (Menthol), Mupirocine, Ice throat candy (Menthol), Tamiflu (Oseltamivir), Naphazoline hydrochloride nasal drops, Fisherman's Friend, Cromoglycate, Sinex (Phenylephrine Hydrochloride), Fluticasone propionate spray, Chloraseptic (Menthol/ Benzocaine), NasoGEL (NeilMed), CVS Nasal Spray (Cromolyn), Saline Nasal Spray, Zicam Cold Remedy, Homeopathic (Alkalol), Sodium Cromolyn Eye Drops, Alkalol Nasal Wash, Throat Lozenge, Sore throat phenol throat

PRECAUTIONS

1.For self-testing in-vitro diagnostic use only.

2.Do not use the kit contents beyond the expiration date printed on the outside of the box.

- 3.Do not reuse the used Test Card, Reagent Tube or Swab.
- 4. The aluminum pouch includes a test cassette and a silica gel. Silica gel is required for protect test cassette against environmental conditions. Do not use the test kit if the aluminum pouch does not include silica gel. Do not swallow the silica gel. When swallowed, immediately consult your healthcare professional.
- 5.All users must read the instructions for use carefully before carrying out

6. The sample buffer and test cassette must be brought to room temperature (18°C~30°C) before use, otherwise the results may be false.

7. Discard and do not use any damaged or dropped Test Card or material. 8. Users should test specimens as soon as possible after collection

if the sample does not store in sample extraction solution. 9.Do not spill any of the sample extraction solution. If you spill it, sterilize the area and if the amount of the sample extraction solution mixture is not enough to perform the test, repeat the test bey using new sampling swab and extraction solution tube

10.Do not drink the extraction solution in the tube with or without swall Immediately consult your healthcare professional if you drink it.

11.If the sample volume is insufficient, the assay will not perform

12. The Reagent Solution contains a salt solution (saline). If the solution contacts the skin or eye, flush with copious amounts of water.

13.Inadequate or inappropriate storage and transport of all components and sample collectionmay yield false test results. 14.To obtain accurate results, do not use visually bloody or overly viscous

specimens. 15. To obtain accurate results, an opened and exposed Test Card should not

be used in a heavily ventilated and moisture area. 16.Wash hands thoroughly after handling

17 Do not touch the sample well or the membrane of the test cassette 18. Keep out of reach of children

COMPONE	Material included	BUFFE	R Sample Buffer
11	This Side Up	IVD	In Vitro Diagnostic Medical Device
Y	Fragile	类	Keep Away From Sunlight
I FU	Instruction for Use	~~	Date of Manufacture
Ωi	Consult Instruction for Use	REF	Reference Number
Warning	Warning	8	Do Not Reuse
2°C 20°C 30°F 80°F	Store at 2°C ~ 30°C	LOT	Lot Number
Ω	Expiration Date	$\overline{\mathbb{V}}_{1}$	Tests per Kit
444	Manufacturer	®	Do not use if the package is damaged
<u> </u>	Keep Dry		

STATE AND TERRITORY CONTACT NUMBERS

Medical Device Incident Report

You can contact the Therapeutic Goods Administration (TGA) to
report performance or usability issues via the online Users Medical
Device Incident Report, emailling iris@tga.gov.au or calling 1800 809 361.

ocal state and territory health departments
Contact details and websites of the local state and territory health departments

Australian Capital Territory Coronavirus Helplin ronavirus helpline (8am to 8pm daily): 02 6207 7244 Isiness hours: 02 5124 9213 Website: https://health.act.gov.au/

New South Wales Department of Health General enquiries: 1300 066 055 onavirus hotline (Service NSW, 24/7): 137 788

Vebsite: https://www.health.nsw.gov.au

Northern Territory Department of Health General enquiries: 08 8922 8044 Coronavirus hotline (National helpline): 1800 020 080 Website: https:// ealth.nt.gov.au/

•Queensland Department of Health

General enquiries: 13HEALTH or 13 432 584 Coronavirus hotline: 134COVID or 134 268 Website: https://www.health.qld.gov.au/

•South Australian Department of Health General enquiries: 1300 232 272

Coronavirus hotline (9am to 5pm daily): 1800 253 787 Website: https://www.sahealth.sa.gov.au

•Tasmanian Department of Health General enquiries:1300 135 513 Public Health Hotline (coronavirus) 1800 671 738

Website: https://www.health.tas.gov.au/

•Victorian Department of Health Department of Health and Human Services: 1300 650 172 Victorian coronavirus hotline (24/7): 1800 675 398 Website: https://www.dhhs.vic.gov.au/

•Western Australian Department of Health General enquiries: 08 9222 4222 Coronavirus hotline: 13COVID (8am to 6pm, Mon–Fri) or 1800 595 206 Website https://www.healthywa.wa.gov.au/

Australia Sponsor & Distributor Touch Biotechnology Pty Ltd

Customer Support Number: 1300 166 282

Hours: 9am-7pm (AEST), or 9am-8pm (AEDT), 7 days per week

Website: www.touchaustralia.com.au Email: touch@touchaustralia.com.au. Address: 119 Willoughby Road, Crows Nest, NSW 2065



Code:RSV-IFU Date of Issue:21.04.2023 Version: 01202303_07